Trials / Terminated
TerminatedNCT05020873
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 16 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, prospective, single-arm observational non-interventional study (NIS), which will be conducted in various countries in the Middle East and India.
Detailed description
The study is designed to collect information on the utilization and effectiveness of crizanlizumab treatment in SCD patients under routine clinical practice conditions, to which the physician has made an independent decision to prescribe crizanlizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Crizanlizumab | Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled. |
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
- First posted
- 2021-08-25
- Last updated
- 2024-06-24
Locations
5 sites across 4 countries: Bahrain, Kuwait, Qatar, Saudi Arabia
Source: ClinicalTrials.gov record NCT05020873. Inclusion in this directory is not an endorsement.